But the surge in Chinese pharma is still ringing alarm bells. “China’s rise in biotech is a threat to the United States,” ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Novo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

What matters in U.S. and global markets today By Mike Dolan, Editor-At-Large, Finance and Markets The glass appears half full once again. With midyear approaching, the main Wall Street stock indexes ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Insurance coverage for weight-loss drugs has recently increased, but typically only covers branded versions, according to ...

European stocks rose sharply Friday after U.S. Commerce Secretary Howard Lutnick said the U.S. and China had agreed to restore their trade truce and that more deals were imminent. Also lifting the ...

Biocon has scrapped its plans to introduce generic versions of Novo Nordisk's Ozempic and Wegovy in China, citing intense ...